Intercept Pharmaceuticals (ICPT) Announces Preclinical Data Demonstrating OCA's Potential Role In Preventing Complications Of Cirrhosis
4/11/2014 6:59:17 AM
NEW YORK, April 11, 2014 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) (Intercept) today announced results from a preclinical study demonstrating the potential protective effects of the Company's lead product candidate obeticholic acid (OCA) in an experimental model of liver disease. The study was presented orally during the opening session of the International Liver Congress™ 2014, the 49th Annual Meeting of the European Association for the Study of the Liver (EASL) in London. The study has also been selected as the best oral abstract in Basic Science at ILC 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by